Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates
Pauline Maisonnasse, Jérémie Guedj, Vanessa Contreras, Sylvie Behillil, Caroline Solas, Romain Marlin, Thibaut Naninck, Andres Pizzorno, Julien Lemaitre, Antonio Gonçalves, Nidhal Kahlaoui, Olivier Terrier, Raphael Ho Tsong Fang, Vincent Enouf, Nathalie Dereuddre-Bosquet, Angela Brisebarre, Franck Touret, Catherine Chapon, Bruno Hoen, Bruno Lina, Manuel Rosa Calatrava, Sylvie Van Der Werf, Xavier De Lamballerie, Roger Le Grand
Nature, doi:10.1038/s41586-020-2558-4
This is a PDF file of a peer-reviewed paper that has been accepted for publication. Although unedited, the content has been subjected to preliminary formatting. Nature is providing this early version of the typeset paper as a service to our authors and readers. The text and figures will undergo copyediting and a proof review before the paper is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers apply.
Reporting summary Further information on research design is available in the Nature Research Reporting Summary linked to this paper. Acknowledgements Delache B, Burban E, Demilly J, Dhooge N, Langlois S, Le Calvez P, Potier M, Relouzat F, Robert JM and Dodan C contributed to animal studies. Fert B and Mayet C contributed to in vivo imaging studies. Pascal Q performed the necropsies. Morin J did the cytokines measurements and reagents preparation. Barthelemy K, Basso M, Doudka N, Giocanti M, contributed to HCQ concentration measurements. Lacarelle B and Guilhaumou R contributed to internal drug concentration data. Bertrand J contributed to pharmacokinetics analysis. Desjardins D contributed to the AZTH pharmacokinetic study. Aubenque C, Barendji M, Bossevot L, Dimant N, Dinh J, Gallouet AS, Leonec M, Mangeot I and Storck K contributed to sample processing. Albert M., Barbet M. and Donati F contributed to the production, titration and sequencing of the virus stocks used in vivo and to processing of samples for RT-PCR. Gallouet AS, Keyser, S, Marcos-Lopez E, Targat B and Vaslin B helped to experimental studies in the context of COVID-19 induced constraints. Ducancel F and Gorin Y contributed to logistics and safety management. We are very grateful for the help of Dr Sultan E from Sanofi for providing guidance in HCQ dose selection and discussion on PK/PD results and the review of the article. We thank Sanofi for providing the hydroxychloroquine batch used in these experiments...
References
Chen, Clinical and immunological features of severe and moderate coronavirus disease 2019, J Clin Invest,
doi:10.1172/jci137244
Chen, Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, Lancet,
doi:10.1016/s0140-6736(20)30211-7
Chhonker, Sleightholm, Li, Oupicky, Murry, Simultaneous quantitation of hydroxychloroquine and its metabolites in mouse blood and tissues using LC-ESI-MS/MS: An application for pharmacokinetic studies, J Chromatogr B Analyt Technol Biomed Life Sci,
doi:10.1016/j.jchromb.2017.11.026
De Lamballerie, Characterization of cellular transcriptomic signatures induced by different respiratory viruses in human reconstituted airway epithelia, Sci Rep,
doi:10.1038/s41598-019-48013-7
Fanouriakis, Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ ERA-EDTA) recommendations for the management of lupus nephritis, Ann Rheum Dis,
doi:10.1136/annrheumdis-2020-216924
Gautret, Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study, Travel Med Infect Dis,
doi:10.1016/j.tmaid.2020.101663
Li, Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia, N Engl J Med,
doi:10.1056/NEJMoa2001316
Liu, Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov,
doi:10.1038/s41421-020-0156-0
Monzavi, Efficacy analysis of hydroxychloroquine therapy in systemic lupus erythematosus: a study on disease activity and immunological biomarkers, Inflammopharmacology,
doi:10.1007/s10787-018-0512-y
Rainsford, Parke, Clifford-Rashotte, Kean, Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases, Inflammopharmacology,
doi:10.1007/s10787-015-0239-y
Roques, Paradoxical Effect of Chloroquine Treatment in Enhancing Chikungunya Virus Infection, Viruses,
doi:10.3390/v10050268
Schrezenmeier, Dorner, Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology, Nat Rev Rheumatol,
doi:10.1038/s41584-020-0372-x
Tett, Cutler, Day, Brown, A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers, Br J Clin Pharmacol,
doi:10.1111/j.1365-2125.1988.tb05281.x
Touret, vitro</em> screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication, bioRxiv,
doi:10.1101/2020.04.03.023846
Wang, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res,
doi:10.1038/s41422-020-0282-0
Yao, Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Clin Infect Dis,
doi:10.1093/cid/ciaa237
Zhang, Macrolide derivatives reduce proinflammatory macrophage activation and macrophage-mediated neurotoxicity, CNS Neurosci Ther,
doi:10.1111/cns.13092